Literature DB >> 17408660

Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus.

Ganapathy A Prasad1, Kenneth K Wang, Navtej S Buttar, Louis-Michel Wongkeesong, Kausilia K Krishnadath, Francis C Nichols, Lori S Lutzke, Lynn S Borkenhagen.   

Abstract

BACKGROUND & AIMS: Photodynamic therapy (PDT) for high-grade dysplasia (HGD) in Barrett's esophagus is a Food and Drug Administration-approved alternative to esophagectomy. Critical information regarding overall survival of patients followed up long-term after these therapies is lacking. Our aim was to compare the long-term survival of patients treated with PDT with patients treated with esophagectomy.
METHODS: We reviewed records of patients with HGD seen at our institution between 1994 and 2004. PDT was performed 48 hours following the intravenous administration of a photosensitizer using light at 630 nm. Esophagectomy was performed by either transhiatal or transthoracic approaches by experienced surgeons. We excluded all patients with evidence of cancer on biopsy specimens. Vital status and death date information was queried using an institutionally approved Internet research and location service. Statistical analysis was performed using Kaplan-Meier curves and Cox proportional hazards ratios.
RESULTS: A total of 199 patients were identified. A total of 129 patients (65%) were treated with PDT and 70 (35%) with esophagectomy. Overall mortality in the PDT group was 9% (11/129) and in the surgery group was 8.5% (6/70) over a median follow-up period of 59 +/- 2.7 months for the PDT group and 61 +/- 5.8 months for the surgery group. Overall survival was similar between the 2 groups (Wilcoxon test = 0.0924; P = .76). Treatment modality was not a significant predictor of mortality on multivariate analysis.
CONCLUSIONS: Overall mortality and long-term survival in patients with HGD treated with PDT appears to be comparable to that of patients treated with esophagectomy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17408660      PMCID: PMC2646409          DOI: 10.1053/j.gastro.2007.02.017

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  42 in total

1.  What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.

Authors:  N J Shaheen; J M Inadomi; B F Overholt; P Sharma
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

2.  Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia.

Authors:  Oliver Pech; Liebwin Gossner; Andrea May; Thomas Rabenstein; Michael Vieth; Manfred Stolte; Manfred Berres; Christian Ell
Journal:  Gastrointest Endosc       Date:  2005-07       Impact factor: 9.427

3.  The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years.

Authors:  D J Drewitz; R E Sampliner; H S Garewal
Journal:  Am J Gastroenterol       Date:  1997-02       Impact factor: 10.864

4.  Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

Authors:  R B D'Agostino
Journal:  Stat Med       Date:  1998-10-15       Impact factor: 2.373

5.  Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial.

Authors:  Bergein F Overholt; Charles J Lightdale; Kenneth K Wang; Marcia I Canto; Steven Burdick; Roger C Haggitt; Mary P Bronner; Shari L Taylor; Michael G A Grace; Michelle Depot
Journal:  Gastrointest Endosc       Date:  2005-10       Impact factor: 9.427

6.  Surgical treatment of esophageal high-grade dysplasia.

Authors:  Michael F Reed; George Tolis; Barish H Edil; James S Allan; Dean M Donahue; Henning A Gaissert; Ashby C Moncure; John C Wain; Cameron D Wright; Douglas J Mathisen
Journal:  Ann Thorac Surg       Date:  2005-04       Impact factor: 4.330

7.  The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry.

Authors:  J B O'Connor; G W Falk; J E Richter
Journal:  Am J Gastroenterol       Date:  1999-08       Impact factor: 10.864

8.  Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study.

Authors:  A J Cameron; H A Carpenter
Journal:  Am J Gastroenterol       Date:  1997-04       Impact factor: 10.864

Review 9.  An electronic application for rapidly calculating Charlson comorbidity score.

Authors:  William H Hall; Ramanathan Ramachandran; Samir Narayan; Ashesh B Jani; Srinivasan Vijayakumar
Journal:  BMC Cancer       Date:  2004-12-20       Impact factor: 4.430

10.  Laparoscopic transhiatal esophagectomy for Barrett's esophagus with high grade dysplasia.

Authors:  J D Luketich; N T Nguyen; P R Schauer
Journal:  JSLS       Date:  1998 Jan-Mar       Impact factor: 2.172

View more
  70 in total

1.  [Endoscopic and surgical resection of mucosal adenocarcinoma in Barrett's esophagus : Comparison at two high-volume centers].

Authors:  L Haeder; J Jähne
Journal:  Chirurg       Date:  2012-01       Impact factor: 0.955

2.  Endoscopic treatments for early esophageal cancer.

Authors:  Charles J Lightdale
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-12

3.  Barrett's Esophagus: A Review of Biology and Therapeutic Approaches.

Authors:  Panteleimon Kountourakis; Jaffer A Ajani; Marta Davila; Jeffrey H Lee; Manoop S Bhutani; Julie G Izzo
Journal:  Gastrointest Cancer Res       Date:  2012-03

Review 4.  Endoscopic management of Barrett's esophagus: advances in endoscopic techniques.

Authors:  Ali Azarm; Ismet Lukolic; Meenal Shukla; Ronald Concha-Parra; Frank Gress
Journal:  Dig Dis Sci       Date:  2012-07-04       Impact factor: 3.199

Review 5.  Guidelines for surgical treatment of gastroesophageal reflux disease.

Authors:  Dimitrios Stefanidis; William W Hope; Geoffrey P Kohn; Patrick R Reardon; William S Richardson; Robert D Fanelli
Journal:  Surg Endosc       Date:  2010-08-20       Impact factor: 4.584

6.  Barrett's esophagus and the increasing role of endoluminal therapy.

Authors:  Michael S Smith; Charles J Lightdale
Journal:  Therap Adv Gastroenterol       Date:  2008-09       Impact factor: 4.409

7.  Are We Making Progress in Preventing Barrett's-Related Esophageal Cancer?

Authors:  Julian A Abrams
Journal:  Therap Adv Gastroenterol       Date:  2009-03       Impact factor: 4.409

Review 8.  An evolutionary perspective on field cancerization.

Authors:  Kit Curtius; Nicholas A Wright; Trevor A Graham
Journal:  Nat Rev Cancer       Date:  2017-12-08       Impact factor: 60.716

9.  In vivo endomicroscopy improves detection of Barrett's esophagus-related neoplasia: a multicenter international randomized controlled trial (with video).

Authors:  Marcia Irene Canto; Sharmila Anandasabapathy; William Brugge; Gary W Falk; Kerry B Dunbar; Zhe Zhang; Kevin Woods; Jose Antonio Almario; Ursula Schell; John Goldblum; Anirban Maitra; Elizabeth Montgomery; Ralf Kiesslich
Journal:  Gastrointest Endosc       Date:  2013-11-09       Impact factor: 9.427

10.  Radiofrequency Ablation Is Associated With Decreased Neoplastic Progression in Patients With Barrett's Esophagus and Confirmed Low-Grade Dysplasia.

Authors:  Aaron J Small; James L Araujo; Cadman L Leggett; Aaron H Mendelson; Anant Agarwalla; Julian A Abrams; Charles J Lightdale; Timothy C Wang; Prasad G Iyer; Kenneth K Wang; Anil K Rustgi; Gregory G Ginsberg; Kimberly A Forde; Phyllis A Gimotty; James D Lewis; Gary W Falk; Meenakshi Bewtra
Journal:  Gastroenterology       Date:  2015-04-24       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.